Related Experiment Video

Updated: Mar 12, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.6K

Targeting STAT1 in Both Cancer and Insulin Resistance Diseases

Chen Meng, Li-Bin Guo, Xiaolong Liu1

  • 1The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian Province, P.R. China, 350025.

Current Protein & Peptide Science
|November 19, 2016
PubMed

Insights

Drug repurposing targets key proteins like Signal transducer and activator of transcription 1 (STAT1). Misregulated STAT1 links insulin resistance, obesity, and cancer, offering therapeutic opportunities.

Area of Science:

  • Molecular Biology
  • Oncology
  • Metabolic Diseases

Background:

  • Drug repurposing is a growing strategy in drug development, focusing on drugs targeting key signaling proteins.
  • Insulin resistance, obesity, and cancer are interconnected, potentially through shared molecular pathways.
  • Signal transducer and activator of transcription 1 (STAT1) is a crucial transcription factor implicated in cell proliferation, survival, inflammation, and angiogenesis.

Purpose of the Study:

  • To review the function and regulation of STAT1 in cancer and insulin resistance.
  • To explore drugs and small molecules that modulate STAT1 activity or expression for therapeutic potential.

Main Methods:

  • Literature review of recent research on STAT1.
  • Analysis of STAT1's role in cancer and insulin resistance.
  • Identification of therapeutic agents targeting STAT1.

Main Results:

  • STAT1 expression and activity are dysregulated in both cancer and insulin resistance.
  • STAT1 plays a significant role in cellular processes relevant to these diseases.
  • Several drugs and small molecules show potential for interfering with STAT1.

Conclusions:

  • STAT1 is a critical link between cancer and insulin resistance.
  • Targeting STAT1 offers a promising avenue for drug repurposing in treating these conditions.
Keywords:
CancerSTAT1insulin resistance diseasessignalling pathway

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

11.0K
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

10.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K